Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

M Pharma to pursue dual development approach with weight loss formulation

Friday, January 6, 2017 9:02
% of readers think this story is Fact. Add your two cents.

(Before It's News)

M Pharmaceutical Inc (CNSX:MQ) is to develop both an over-the-counter (OTC) version and a prescription version of its weight loss C-103 orlistat formulation.

Orlistat is the best-selling weight loss medication of all time.

It has a strong safety profile and is approved by the US Food & Drug Administration, but some people on the medication have experienced what can only be described in polite society as anti-social bowel-related side effects from the drug.

M Pharma’s C-103 is a combination of orlistat, simethicone (which reduces bloating) and activated charcoal, and circumvents the side-effects.

Working with its contracted partners, M will develop the foundation required to market 60 milligram (mg) OTC C-103 tablets at the same time as developing the prescription version.

The pharmaceutical company said this dual-stream approach would lower development costs.

The OTC version will be for those who have decided off their own bat, rather than on the advice of a doctor, to lose some weight.

The current plan is to have the OTC C-103 formulation available at pharmacies nationwide in the OTC format and to support it by mass marketing through multimedia channels, including both cable television and digital advertising.

“This long-term strategy will allow the company to address the larger weight loss market for those of the population that may not be technically obese but want a safe alternative to losing weight,” said Gary Thompson, president and chief executive officer of M Pharmaceutical USA.

“Our strategy recognizes that we require a new branding approach for an initial national campaign, followed by the extended campaign into the global marketplace,” he added.

Orlistat is approved for weight management by the US Food and Drug Administration and sold by Roche as Xenical in prescription form and by GlaxoSmithKline as alli in the OTC format.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/171267/m-pharma-to-pursue-dual-development-approach-with-weight-loss-formulation-171267.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.